Summary
The hearing program is comprised of three (3) main tas: ta1 intracortical device(s): ta1 will deliver minimally invasive neural interface(s) to key auditory cortical regions, enabling hearing technologies to be accessible to patients at scale. Approaches may leverage any technology that allows device delivery to target auditory cortex without surgical access through the skull (e. G. , no craniotomy or craniectomy). Neural interfaces are not limited to electronic, biohybrid, ultrasound, or other specific modalities, but proposed technologies must be sufficiently mature at the time of award to meet program schedules and milestones. Ta1 device(s) must support wireless bidirectional communication with ta2 devices and will be assessed for in vivo performance capabilities (e. G. Record and stimulate) and safety as key end-of-phase deliverables. See attached file.